Cargando…

Comparison of recurrent biliary obstruction with the use of metal and plastic stents in EUS-guided biliary drainage: A propensity score-matched analysis

BACKGROUND AND OBJECTIVES: In transpapillary biliary drainage, metal stents (MSs) exhibit a lower incidence of a biliary obstruction than plastic stents (PSs). However, few studies have compared recurrent biliary obstruction (RBO) when MSs and PSs are used in EUS-guided hepaticogastrostomy (EUS-HGS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Shinichi, Iwashita, Yuji, Taguchi, Hiroki, Tanoue, Shiroh, Ohi, Takayuki, Shibata, Ryusuke, Haraguchi, Tomoaki, Kamikihara, Yusuke, Toyodome, Koshiro, Kojima, Issei, Araki, Norimasa, Tsuneyoshi, Kengo, Nakamura, Yoshitaka, Fujita, Toshihiro, Hinokuchi, Makoto, Iwaya, Hiromichi, Arima, Shiho, Sasaki, Fumisato, Kanmura, Shuji, Ido, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134919/
https://www.ncbi.nlm.nih.gov/pubmed/36510868
http://dx.doi.org/10.4103/EUS-D-21-00251
Descripción
Sumario:BACKGROUND AND OBJECTIVES: In transpapillary biliary drainage, metal stents (MSs) exhibit a lower incidence of a biliary obstruction than plastic stents (PSs). However, few studies have compared recurrent biliary obstruction (RBO) when MSs and PSs are used in EUS-guided hepaticogastrostomy (EUS-HGS) and choledochoduodenostomy (EUS-CDS). We retrospectively evaluated the RBO for both stents in each procedure. PATIENTS AND METHODS: Between November 2012 and December 2020, 85 and 53 patients who underwent EUS-HGS and EUS-CDS for unresectable malignant biliary obstruction, respectively, were enrolled. Factors associated with RBO were assessed. Clinical outcomes were compared between the MS and PS groups using propensity score matching. RESULTS: The clinical success rate and procedure-related adverse events were similar in the MS and PS groups. Multivariate analysis identified the use of PS as a factor associated with RBO (EUS-HGS, P = 0.03; EUS-CDS, P = 0.02). After matching, the median time to RBO in EUS-HGS (MS: 313; PS: 125 days; P = 0.01) in the MS group was longer than that in the PS group. The cumulative incidence of RBO at 1, 3, and 6 months in the MS group was significantly lower than that in the PS group for EUS-HGS (MS: 4.0%, 8.2%, and 8.2%; PS: 12.4%, 24.9%, and 39.5%, respectively, P = 0.01). CONCLUSIONS: MS exhibited a lower rate of RBO than PS for EUS-HGS and EUS-CDS.